Skip to main content

Advertisement

SpringerLink
Log in

Antibodies in human infectious disease

  • Published:
Immunologic Research Aims and scope Submit manuscript

Abstract

Investigation of human antibody responses to viral pathogens at the molecular level is revealing novel aspects of the interplay of viruses with the humoral immune system. In viral infection, at least two types of human antibody responses exist: a response to mature envelope on virions that is neutralizing and a response to immature forms of envelope (viral debris) that is not. Many pathogens have, to varying degrees, evolved envelopes to minimize antibody responses against epitopes exposed on the viron. In this article, we review recent studies on human immunodeficiency virus type 1, Ebola virus, and respiratory syncytial virus. Prion diseases are diseases of protein conformation. We have generated a large panel of antibodies recognizing the cellular prion protein (PrPc), some of which also react with the abnormally folded infectious prion protein (PrPSc). These antibodies are being used to gain insight into both the molecular events leading to the formation of infectious PrP and the physiologic role played by PrP in normal and prion-infected cells.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Garrett L: The Coming Plague: Newly Emerging Diseases in a World Out of Balance. New York, Famar, Straus and Giroux, 1994.

    Google Scholar 

  2. World Health Organization Geneva: Global AIDS surveillance part II. Weekly Epidemiol Rec 1998;73:381–384.

    Google Scholar 

  3. Moore JP, Burton DR: HIV-1 neutralizing antibodies: how full is the bottle? Nat Med 1999;5:142–144.

    Article  PubMed  CAS  Google Scholar 

  4. Shibata R, Igarashi T, Haigwood N, Buckler-White A, Ogert R, Ross W, Willey R, Cho MW, Martin MA: Neutralizing antibodies directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nat Med 1999;5:205–210.

    Article  CAS  Google Scholar 

  5. Parren PWHI, Gauduin M-C, Koup RA, Poignard P, Sattentau QJ, Fisicaro P, Burton DR: Relevance of the antibody response against human immunodeficiency virus type 1 envelope to vaccine design. Immunol Lett 1997;58:125–132.

    Article  PubMed  CAS  Google Scholar 

  6. Gauduin M-C, Parren PWHI, Weir R, Barbas CF, Burton DR, Koup RA: Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1. Nat Med 1997;3:1389–1393.

    Article  PubMed  CAS  Google Scholar 

  7. Burton DR, Moore JP: Why do we not have an HIV vaccine and how can we make one? Nat Med 1998; 4:495–498.

    Article  PubMed  CAS  Google Scholar 

  8. Parren PWHI, Moore JP, Burton DR, Sattentau QJ: The neutralizing antibody response to HIV-1: viral evasion and escape from humoral immunity. AIDS 1999; 13(Suppl. A):S137-S162.

    PubMed  CAS  Google Scholar 

  9. Burton DR, Pyati J, Koduri R, et al.: Efficient neutralization of primary isolates of HIV-1 by a tecombinant human monoclonal antibody. Science 1994;266:1024–1027.

    Article  PubMed  CAS  Google Scholar 

  10. Burton DR, Barbas CF, Persson MAA, Koenig S, Chanock RM, Lerner RA: A largearray of human monoclonal antibodies to type 1 human immuno deficiency virus from combinatorial libraries of asymptomatic seropositive individuals. Proc Natl Acad Sci USA 1991;88:10,134–10,137.

    Article  CAS  Google Scholar 

  11. Ditzel HJ, Parren PWHI, Binley JM, Sodroski J, Moore JP, Barbas CF, Burton DR: Mapping the protein surface of human immunodeficiency virus type 1 gp 120 using human monoclonal antibodies from phage display libraries. J Mol Biol 1997;267:684–695.

    Article  PubMed  CAS  Google Scholar 

  12. Burton DR: A vaccine for HIV type 1: the antibody perspective. Proc Natl Acad Sci USA 1997;94: 10,018–10,023.

    CAS  Google Scholar 

  13. Labrijn AF, Parren PwHI: Neutralizing epitopes of HIV-1. Los Alamos, NM, HIV Molecular Immunology Database. Los Alamos National Laboratory (http://hiv-web.lanl.gov/immunol ogy/), 2000.

  14. Barbas CF, Kang AS, Lerner RA, Benkovic SJ: Assembly of combinatorial antibody libraries on phage surfaces: the gene III site. Proc Natl Acad Sci USA 1991; 88:7978–7982.

    Article  PubMed  CAS  Google Scholar 

  15. Parren PWHI, Burton DR: Antibodies against HIV-1 from phage display libraries: mapping of an immune response and progress towands anti-viral immunotherapy. Chem Immunol 1997;65:18–56.

    PubMed  CAS  Google Scholar 

  16. Slifka MK, Antia R, Wimire JK, Ahmed R: Humoral immunity due to long-lived plasma cells. Immunity 1998;8:363–372.

    Article  PubMed  CAS  Google Scholar 

  17. Leyendeckers H, Odendahl M, Löhndorf A, Irsch J, Spangfort M, Miltenyi S, Hunzelmann N, Assenmacher M, Radbruch A, Schmitz J: Correlation analysis between frequencies of circulating antigen-specific IgG-bearing memory B cells and serum titers of antigen-specific IgG. Eur J Immunol 1999;29:1406–1417.

    Article  PubMed  CAS  Google Scholar 

  18. Williamson RA, Burioni R, Sanna PP, partridge LJ, Barbas CF, Burton DR: Human monoclonal antibodies against a plethora of viral pathogens from single combinatorial libraries. Proc Natl Acad Sci USA 1993;90:4141–4145.

    Article  PubMed  CAS  Google Scholar 

  19. Parren PWHI, Fisicaro P, Labrijn AF, Binley JM, Yang W-P, Ditzel HJ, Barbas CF, Burton DR: In vitro antigen challenge of human antibody libraries for vaccine evaluation: the human immuno deficiency virus type 1 envelope. J Virol 1996;70(12):9046–9050.

    PubMed  CAS  Google Scholar 

  20. Moore JP, Ho DD: HIV-1 neutralization: the conse quences of viral adaptation to growth on transformed T cells. AIDS 1995; 9(Suppl A):S117-S136.

    PubMed  Google Scholar 

  21. Cohen J: Jitters jeopardize AIDS vaccine trials. Science 1993;262:980.981.

    PubMed  Google Scholar 

  22. Trkola A, Purtscher M, Muster T, Ballaun C, Buchacher A, Sullivan N, Srinivasan K, Sodroski J, Moore JP, Katinger H: Human monoclonal antibody 2G12 defines adistinctive neutralization epitope on the gpl 20 glycoprotein of human immunodeficiency virus type 1. J Virol 1996;70:1100–1108.

    PubMed  CAS  Google Scholar 

  23. Muster T, Steindl F, Purtscher M, Trkola A, Klima A, Himmler G, Rüker F, Katinger H: A conserved neutralzing epitope on gp41 of human immunodeficiency virus type 1. J Virol 1993;67:6642–6647.

    PubMed  CAS  Google Scholar 

  24. Dimmock NJ: Neutralization of animal viruses. Cur Top Microbiol 1993;183:1–149.

    CAS  Google Scholar 

  25. Ugolini S, Mondor I, Parren PWHI, Burton DR, Tilley SA, Klasse PJ, Sattentau QJ: Inhibition of attachement to CD4+ target cells is a major mechanism of T celline-adapted HIV-1 neutralization. J Exp Med 1997;186:1287–1298.

    Article  PubMed  CAS  Google Scholar 

  26. Parren PWHI, Mondor I, Naniche D, Ditzel HJ, Klasse PJ, Burton DR, Sattentau QJ: Neutralization of HIV-1 by antibody to gp120 is determined primarily by occupancy of sites on the virion irrespective of epitope specificity. J Virol 1998;72:3512–3519.

    PubMed  CAS  Google Scholar 

  27. Roben P, Moore JP, Thali M, Sodroski J, Barbas CF, Burton DR: Recognition properties of a panel of human recombinat Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1. J Virol 1994; 68:4821–4828.

    PubMed  CAS  Google Scholar 

  28. Sattentau QJ, Moore JP: Human immuno deficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer. J Exp Med 1995;182:185–196.

    Article  PubMed  CAS  Google Scholar 

  29. Schonning K, Lund O, Lund OS, Hanssen J-ES: Stoichiometry of monoclonal antibody neutralization of T-cell line-adapted human immunodeficiency virus type 1. J Virol 1999;73:8364–8370.

    PubMed  CAS  Google Scholar 

  30. Chan DC, Kim PS: HIV entry and its inhibition. Cell 1998;93:681–684.

    Article  PubMed  CAS  Google Scholar 

  31. Parren PWHI, Sattentau QJ, Burton DR: HIV-1 antibody—debris or virion? Nat Med 1997; 3:367–368.

    Article  Google Scholar 

  32. Parren PWHI, Ditzel HJ, Gulizia RJ, Binley JM, Barbas CF, Burton DR, Mosier DE: Protectionagainst HIV-1 infection in hu-PBL-SCID mice by passive immunization with a neutralizing human monoclonal antibody against the gp120 CD4-binding site. AIDS 1995;9:F1-F6.

    Article  PubMed  CAS  Google Scholar 

  33. Gauduin M-C, Parren PWHI, Weir R, Barbas CF, Burton DR, Koup RA: Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1. Nat Med 1997;3:1389–1393.

    Article  PubMed  CAS  Google Scholar 

  34. Mascola JR, Lewis MG, Stiegler G, et al.: Protection of macaques against pathogenic SHIV-89.6PD by passive transfer of neutralizing antibodies. J Virol 1999;73:4009–4018.

    PubMed  CAS  Google Scholar 

  35. Foresman L, Jia F, Li Z, Wang C, Stephens EB, Sahni M, Narayan O, Joag SV: Neutralizing antibodies administered before, but not after, virulent SHIV prevent infection in macaques. AIDS Res Hum Retroviruses 1998;14:1035–1043.

    Article  PubMed  CAS  Google Scholar 

  36. Dittmer U, Brooks DM, Hasenkrug KJ: Requirement for multiple lymphocyte subsets in protection against retroviral infection by a live-attenuated vaccine. Nat Med 1999;5:189–193.

    Article  PubMed  CAS  Google Scholar 

  37. Poignard P, Sabbe S, Picchio GR, Wang M, Gulizia RJ, Katinger H, Parren PWHI, Mosier DE, Burton DR: Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo. Immunity 1999;10:1–20.

    Article  Google Scholar 

  38. Parren PWHI, Wang M, Trkola A, Binley JM, Purtscher M, Katinger H, Moore JP, Burton DR: Antibody neutralization-resistant primary isolates of human immunodeficiency virus type-1. J Virol 1998; 72:10,270–10,274.

    CAS  Google Scholar 

  39. Mo H, Stamatatos L, Ip JE, Barbas CF, Parren PWHI, Burton DR, Moore JP, Ho DD: Human immunodeficiency virus type 1 mutants that escape neutralization by human monoclonal antibody IgG1 b12. J Virol 1997;71(9):6869–6874.

    PubMed  CAS  Google Scholar 

  40. Barbas CF, Crowe JE Jr, Cababa D, Jones TM, Zebedee SL, Murphy BR, Chanock RM, Burton DR: Human monoclonal Fab fragments derived from a combinatorial library bind to respiratory syncytial virus F glycoprotein and neutralize infectivity. Proc Natl Acad Sci USA 1992;89: 10,164–10,168.

    CAS  Google Scholar 

  41. Crowe JE Jr, Murphy BR, Chanock RM, Williamson RA, Barbas CF, Burton DR: Recombinant human respiratory syncytial virus (RSV) monoclonal antibody Fab is effective therapeutically when introduced directly into the lungs of RSV-infected mice. Proc Natl Acad Sci USA 1994;91:1386–1390.

    Article  PubMed  CAS  Google Scholar 

  42. Sakurai H, Williamson RA, Crowe JE, Beeler JA, Poignard P, Bastidas RB, Chanock RM, Burton DR: Human antibody responses to mature and immature forms of viral envelope in respiratory syncytial virus infection: significance for subunit vaccines. J Virol 1999; 65:18–56.

    Google Scholar 

  43. Maruyama T, Parren PWHI, Sanchez A, Rensink I, Rodriguez LL, Khan A, Peters CJ, Burton DR: Recombinant human monoclonal antibodies to Ebola virus. J Infect Dis 1999;179:S235-S239.

    PubMed  CAS  Google Scholar 

  44. Maruyama T, Rodriguez LL, Jahrling PB, Sanchez A, Khan A, Nichol ST, Peters CJ, Parren PWHI, Burton DR: Ebola virus can be effectively neutralized by antibody produced in natural human infection. J Virol 1999;73:6024–6030.

    PubMed  CAS  Google Scholar 

  45. Cohen FE: Protein misfolding and prion diseases. J Mol Biol 1999; 293:313–320.

    Article  PubMed  CAS  Google Scholar 

  46. Harris DA: Cellular biology of prion diseases. Clin Microbiol Rev 1999;12:429–444.

    PubMed  CAS  Google Scholar 

  47. Collinge J, Sidle KCL, Meads J, Ironside J, Hill AF: Molecular analysis of prion strain variation and the aetiology of ‘new variant’ CJD. Nature 1996;383:685–690.

    Article  PubMed  CAS  Google Scholar 

  48. Bruce ME, Will RG, Ironside JW, et al.: Transmissions to mice indicate that ‘new variant’ CJD is caused by the BSE agent. Nature 1999;389:498–501.

    Article  CAS  Google Scholar 

  49. Hill AF, Desbruslais M, Joiner S, Sidle KC, Gowland I, Collinge J, Doey LJ, Lantos P: The same prion strain causes vCJD and BSE. Nature 1997;389:448–450.

    Article  PubMed  CAS  Google Scholar 

  50. Knight R, Stewart G: The new variant form of Creutzfeldt-Jakob disease. FEMS Immunol Med Microbiol 1998;21:97–100.

    PubMed  CAS  Google Scholar 

  51. Anderson RM, Donnelly CA, Ferguson NM, et al.: Transmission dynamics and epidemiology of BSE in British cattle. Nature 1996; 382:779–788.

    Article  PubMed  CAS  Google Scholar 

  52. Cohen FE, Pan K-M, Huang Z, Baldwin M, Fletterick RJ, Prusiner SB: Structural clues to prion replication. Science 1994; 264:530–531.

    Article  PubMed  CAS  Google Scholar 

  53. Pan K-M, Baldwin M, Nguyen J, et al.: Conversion of α-helices into β-sheets features in the formation of the scrapie prion protein. Proc Natl Acad Sci USA 1993;90:10,926–10,966.

    Google Scholar 

  54. Zhang H, Stockel J, Melhorn I, Groth D, Baldwin MA, Prusiner SB, James TL, Cohen FE: Physical studies of conformational plasticity in a recombinant prion protein. Biochemistry 1997;36:3543–3553.

    Article  PubMed  CAS  Google Scholar 

  55. Riek R, Hornemann S, Wider G, Glockshuber R, Wuthrich K: NMR characterization of the full-length recombinant murine prion protein, mPrP (23–231). FEBS Lett 1997; 413:282–288.

    Article  PubMed  CAS  Google Scholar 

  56. Riek R, Hornemann S, Wider G, Billeter M, Glockshuber R, Wuthrich K: NMR structure of the mouse prion protein domain PrP (121–231). Nature 1996;382:180–182.

    Article  PubMed  CAS  Google Scholar 

  57. Donne DG, Viles JH, Groth D, Mehlhorn I, James TL, Cohen FE, Prusiner SB, Wright PE, Dyson HJ: Structure of the recombinant full-length hamster prion protein PrP (29–231): the N-terminus is highly flexible. Proc Natl Acad Sci USA 1997;94:13,452–13,457.

    Article  CAS  Google Scholar 

  58. Peretz D, Williamson RA, Matsunaga Y, et al.: A conformational transition at the N-terminus of the prion prote in features in formation of the scrapie iso form. J Mol Biol 1997;273:614–622.

    Article  PubMed  CAS  Google Scholar 

  59. Prusiner SB: Prions. PNAS 1998; 95:13,363–13,383.

    Article  CAS  Google Scholar 

  60. Safar J, Wille H, Itri V, Groth D, Serban H, Torchia M, Cohen FE, Prusiner SB: Eight prion strains have PrPSc molecules with different conformations. Nat Med 1998; 4:1157–1165.

    Article  PubMed  CAS  Google Scholar 

  61. Kanyo ZF, Pan KM, Williamson RA, Burton DR, Prusiner SB, Fletterick RJ, Cohen FE: Antibody binding defines a structure for an epitope that participates in the PrP(C)→PrP (Sc) conformational change. J Mol Biol 1999;293:855–863.

    Article  PubMed  CAS  Google Scholar 

  62. Williamson RA, Peretz D, Pinilla C, Ball H, Bastidas RB, Rozen

Download references

Author information

Author notes

  1. Dennis R. Burton

    Present address: Department of Immunology, The Scripps Research Institute, 10550 N Torrey Pines Road, 92037, La Jolh, CA

Authors and Affiliations

  1. Department of Immunology, The Scripps Research Institute, 10550 N Torrey Pines Road, 92037, La Jolh, CA

    Paul W. H. I. Parren, Pascal Poignard, Henrick J. Ditzel & R. Anthony Williamson

Authors
  1. Paul W. H. I. Parren
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pascal Poignard
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Henrick J. Ditzel
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R. Anthony Williamson
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Dennis R. Burton
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Parren, P.W.H.I., Poignard, P., Ditzel, H.J. et al. Antibodies in human infectious disease. Immunol Res 21, 265–278 (2000). https://doi.org/10.1385/IR:21:2-3:265

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1385/IR:21:2-3:265

Key Words

Search

Navigation